longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Veracyte

VCYT

43.3604.43% ( +1.840 )
Closed: Sep 22, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 29.16, below the reasonable range, cheaper than 93.87% of the time in the past 1 years, and the industry ranks 45/602, the industry Median -2.44.

29.16xP/E
$41.52Stock price
$1.42Earnings per share
29.16xP/E
Stock price$41.52Earnings per share$1.42

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
50.88x
Typical range
37.04x–108.39x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
AMGNUSAmgen
24.31x10.95%$212.55B
VRTXUSVertex Pharma
29.39x36.49%$129.45B
REGNUSRegeneron Pharma
18.98x4.10%$82.18B
INCYUSIncyte
15.67x65.04%$25.27B
GMABUSGenmab A/S
27.07x24.93%$21.33B
UTHRUSUnited Therap
16.13x6.53%$21.15B
ASNDUSAscendis Pharmac
18.15x477.43%$15.63B
NBIXUSNeurocrine Biosciences
20.74x50.16%$14.63B
EXELUSExelixis
16.47x16.46%$14.18B
TGTXUSTG Therap
19.82x65.83%$8.75B
VCYTUSVeracyte
29.16x35.02%$3.34B
CDNAUSCaredex
25.32x629.58%$2.81B
MGTXUSMeiraGTx
15.91x122.03%$1.26B
KMDAUSKamada
22.67x39.29%$504.39M
PBYIUSPuma BioTech
18.53x37.70%$495.04M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.